Get the Stockscreener App
17.57
3.44%
-0.455
Avalo Therapeutics Inc stock is traded at $17.57, with a volume of 28,145.
It is down -3.44% in the last 24 hours and up +29.93% over the past month.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
See More
Previous Close:
$18.03
Open:
$18
24h Volume:
28,145
Relative Volume:
0.08
Market Cap:
$233.45M
Revenue:
$1.93M
Net Income/Loss:
$-7.96M
P/E Ratio:
-0.00498
EPS:
-3530.8178
Net Cash Flow:
$-36.78M
1W Performance:
-3.22%
1M Performance:
+29.93%
6M Performance:
+245.44%
1Y Performance:
+34.28%
1-Day Range:
$17.26
$18.66
1-Week Range:
$17.26
$19.01
52-Week Range:
$3.39
$19.41
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
17.75 | 320.93M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.44 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
636.71 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.80 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.56 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.88 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-25 | Initiated | TD Cowen | Buy |
| Aug-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
Avalo Therapeutics Inc expected to post a loss of $1.66 a shareEarnings Preview - TradingView
Avalo Therapeutics to Participate in Upcoming Investor Conferences - Yahoo! Finance UK
Why Avalo Therapeutics Inc. stock remains on watchlists2025 Growth vs Value & Smart Allocation Stock Reports - newser.com
Can Avalo Therapeutics Inc. stock continue upward trendPortfolio Performance Report & Accurate Buy Signal Alerts - newser.com
Avalo Therapeutics, Inc. (AVTX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Will Avalo Therapeutics Inc. stock keep outperforming rivals2025 Technical Overview & Accurate Entry and Exit Point Alerts - newser.com
Can Avalo Therapeutics Inc. stock sustain revenue growthJuly 2025 Technicals & Community Trade Idea Sharing Platform - newser.com
What analyst consensus says on Avalo Therapeutics Inc. stockMarket Rally & AI Driven Price Predictions - newser.com
Why Avalo Therapeutics Inc. (C6K0) stock stays resilient2025 Price Targets & Verified Chart Pattern Trade Signals - newser.com
Multi factor analysis applied to Avalo Therapeutics Inc.Quarterly Investment Review & Precise Buy Zone Identification - newser.com
Using data filters to optimize entry into Avalo Therapeutics Inc.Market Sentiment Report & Real-Time Volume Analysis - newser.com
Full technical analysis of Avalo Therapeutics Inc. stockQuarterly Performance Summary & Daily Volume Surge Signals - newser.com
Will Avalo Therapeutics Inc. (C6K0) stock keep high P E multiplesTrade Analysis Report & Weekly Momentum Picks - newser.com
Is Avalo Therapeutics Inc. (C6K0) stock positioned for secular growthEarnings Miss & Consistent Profit Trading Strategies - newser.com
Real time social sentiment graph for Avalo Therapeutics Inc.Earnings Recap Summary & Entry Point Confirmation Signals - newser.com
How to monitor Avalo Therapeutics Inc. with trend dashboardsJuly 2025 Institutional & Growth Focused Entry Reports - newser.com
Can Avalo Therapeutics Inc. (C6K0) stock sustain revenue momentumCPI Data & Weekly Breakout Stock Alerts - newser.com
Why Avalo Therapeutics Inc. (C6K0) stock remains top ratedJuly 2025 Outlook & AI Powered Trade Plan Recommendations - newser.com
Will Avalo Therapeutics Inc. stock deliver long term returnsJuly 2025 Trends & Weekly Market Pulse Alerts - newser.com
What drives Avalo Therapeutics Inc stock priceWeekly Market Snapshot & Boost Wealth With Growth - earlytimes.in
Avalo Therapeutics Advances in Hidradenitis Suppurativa Treatment with AVTX-009 Study - MSN
Avalo Therapeutics (AVTX) to Release Quarterly Earnings on Thursday - MarketBeat
Is a relief rally coming for Avalo Therapeutics Inc. holdersWeekly Market Summary & Safe Capital Allocation Plans - newser.com
Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX) - Insider Monkey
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa - The Manila Times
Avalo Therapeutics Completes Enrollment in Phase 2 LOTUS Trial - TradingView
Avalo Therapeutics Announces Completion of Enrollment in - GlobeNewswire
Will Avalo Therapeutics Inc. stock outperform Dow Jones indexEarnings Overview Report & AI Powered Market Entry Strategies - fcp.pa.gov.br
Will Avalo Therapeutics Inc. stock deliver consistent dividendsWeekly Volume Report & Risk Controlled Daily Trade Plans - fcp.pa.gov.br
We Think Avalo Therapeutics (NASDAQ:AVTX) Can Afford To Drive Business Growth - Yahoo Finance
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):